Synergy Pharmaceuticals to Present at Jefferies 2013 Global Healthcare
NEW YORK, May 31, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc.
(Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal diseases and
disorders, today announced that its President and CEO, Gary S. Jacob, Ph.D.,
will present at the Jefferies Global Healthcare Conference which is being held
at the Grand Hyatt in New York, NY on Jun 3-6, 2013. The presentation is
scheduled for Thursday, June 6, 2013, at 3:30 p.m. (ET).
Live audio webcast of the presentation will be available under the investor
relations section of Synergy's website at www.synergypharma.com. A replay of
the presentation will also be available and archived on the site for 60 days.
About Synergy Pharmaceuticals, Inc.
Synergy is a biopharmaceutical company focused on the development of new drugs
to treat gastrointestinal (GI) diseases and disorders. Synergy's lead
proprietary drug candidate, plecanatide, is a synthetic analog of the human GI
hormone, uroguanylin, and functions by activating the guanylate cyclase C
receptor on epithelial cells of the GI tract. Synergy completed a positive
Phase I study of plecanatide in healthy volunteers, a positive Phase IIa and
large multicenter clinical trial in patients with chronic idiopathic
constipation. Synergy is also developing plecanatide for the treatment of
irritable bowel syndrome with constipation (IBS-C), having initiated the first
trial in IBS-C patients in late 2012. Synergy's second GC-C agonist, SP-333,
is in clinical development to treat inflammatory bowel diseases, and has
recently completed its first Phase I trial in healthy volunteers. More
information is available at www.synergypharma.com
CONTACT: Media Contact:
The Trout Group
Press spacebar to pause and continue. Press esc to stop.